{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:13:34Z","timestamp":1793297614919,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425004"],"award-info":[{"award-number":["82425004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2021YFA1301200\uff1b2024YFA1307004"],"award-info":[{"award-number":["2021YFA1301200\uff1b2024YFA1307004"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41591-026-04441-3","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:03:20Z","timestamp":1780563800000},"page":"2137-2146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Tao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-7652","authenticated-orcid":false,"given":"Chenbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-4673","authenticated-orcid":false,"given":"Peining","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lailing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9534-2541","authenticated-orcid":false,"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-4934","authenticated-orcid":false,"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-2889","authenticated-orcid":false,"given":"Jianqing","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-5893","authenticated-orcid":false,"given":"Yongbai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-0174","authenticated-orcid":false,"given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-2510","authenticated-orcid":false,"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"4441_CR1","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478\u20133490a (2013).","journal-title":"Eur. Heart J."},{"key":"4441_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.93","volume":"3","author":"JC Defesche","year":"2017","unstructured":"Defesche, J. C. et al. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers 3, 17093 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4441_CR3","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera, A. V. et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67, 2578\u20132589 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4441_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"JL Goldstein","year":"2009","unstructured":"Goldstein, J. L. & Brown, M. S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431\u2013438 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"4441_CR5","doi-asserted-by":"publisher","first-page":"156064","DOI":"10.1016\/j.metabol.2024.156064","volume":"163","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady, A. et al. PCSK9 in metabolism and diseases. Metabolism 163, 156064 (2024).","journal-title":"Metabolism"},{"key":"4441_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2020.07.018","volume":"309","author":"LS Rallidis","year":"2020","unstructured":"Rallidis, L. S. et al. Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. Atherosclerosis 309, 67\u201369 (2020).","journal-title":"Atherosclerosis"},{"key":"4441_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal, F. J. et al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 383, 711\u2013720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4441_CR8","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","volume":"9","author":"F Xue","year":"2022","unstructured":"Xue, F. et al. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol. 9, e504\u2013e513 (2022).","journal-title":"Lancet Haematol."},{"key":"4441_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa2214084","volume":"389","author":"L D\u2019Antiga","year":"2023","unstructured":"D\u2019Antiga, L. et al. Gene therapy in patients with the Crigler\u2013Najjar syndrome. N. Engl. J. Med. 389, 620\u2013631 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4441_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jacl.2016.04.009","volume":"10","author":"JM Foody","year":"2016","unstructured":"Foody, J. M. & Vishwanath, R. Familial hypercholesterolemia\/autosomal dominant hypercholesterolemia: molecular defects, the LDL-C continuum, and gradients of phenotypic severity. J. Clin. Lipidol. 10, 970\u2013986 (2016).","journal-title":"J. Clin. Lipidol."},{"key":"4441_CR11","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman, A. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J. 36, 2425\u20132437 (2015).","journal-title":"Eur. Heart J."},{"key":"4441_CR12","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel, M. et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur. Heart J. 44, 2277\u20132291 (2023).","journal-title":"Eur. Heart J."},{"key":"4441_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","volume":"399","author":"TR Tromp","year":"2022","unstructured":"Tromp, T. R. et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 399, 719\u2013728 (2022).","journal-title":"Lancet"},{"key":"4441_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029175","volume":"12","author":"M Cuchel","year":"2023","unstructured":"Cuchel, M. et al. Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry. J. Am. Heart Assoc. 12, e029175 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"4441_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","volume":"36","author":"B Sjouke","year":"2015","unstructured":"Sjouke, B. et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. 36, 560\u2013565 (2015).","journal-title":"Eur. Heart J."},{"key":"4441_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4441_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jgm.554","volume":"6","author":"C Lebherz","year":"2004","unstructured":"Lebherz, C. et al. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6, 663\u2013672 (2004).","journal-title":"J. Gene Med."},{"key":"4441_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/humc.2017.014","volume":"28","author":"JA Greig","year":"2017","unstructured":"Greig, J. A. et al. Non-clinical study examining AAV8.TBG.hLDLR vector-associated toxicity in chow-fed wild-type and LDLR+\/\u2212 Rhesus macaques. Hum. Gene Ther. Clin. Dev. 28, 39\u201350 (2017).","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"4441_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic, J. et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat. Med. 26, 354\u2013359 (2020).","journal-title":"Nat. Med."},{"key":"4441_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994\u20132004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"4441_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li, C. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 21, 255\u2013272 (2020).","journal-title":"Nat. Rev. Genet."},{"key":"4441_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj5465","volume":"9","author":"P Zhang","year":"2024","unstructured":"Zhang, P. et al. Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA. Sci. Immunol. 9, eadj5465 (2024).","journal-title":"Sci. Immunol."},{"key":"4441_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"H Costa Verdera","year":"2020","unstructured":"Costa Verdera, H., Kuranda, K. & Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723\u2013746 (2020).","journal-title":"Mol. Ther."},{"key":"4441_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ebiom.2017.12.013","volume":"27","author":"X Guo","year":"2018","unstructured":"Guo, X. et al. LDL receptor gene-ablated hamsters: a rodent model of familial hypercholesterolemia with dominant inheritance and diet-induced coronary atherosclerosis. eBioMedicine 27, 214\u2013224 (2018).","journal-title":"eBioMedicine"},{"key":"4441_CR25","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard, B. G. & Langsted, A. Lipoprotein(a) and cardiovascular disease. Lancet 404, 1255\u20131264 (2024).","journal-title":"Lancet"},{"key":"4441_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas, S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J. Am. Coll. Cardiol. 69, 692\u2013711 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4441_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0021-9150(91)90100-H","volume":"86","author":"HC Guo","year":"1991","unstructured":"Guo, H. C., Chapman, M. J., Bruckert, E., Farriaux, J. P. & De Gennes, J. L. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype. Atherosclerosis 86, 69\u201383 (1991).","journal-title":"Atherosclerosis"},{"key":"4441_CR28","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou, J. et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 6, 4266\u20134270 (2022).","journal-title":"Blood Adv."},{"key":"4441_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2021","unstructured":"Chand, D. H. et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J. Pediatr. 231, 265\u2013268 (2021).","journal-title":"J. Pediatr."},{"key":"4441_CR30","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","volume":"32","author":"B Vrellaku","year":"2024","unstructured":"Vrellaku, B. et al. A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders. Mol. Ther. 32, 3220\u20133259 (2024).","journal-title":"Mol. Ther."},{"key":"4441_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","volume":"387","author":"P Chowdary","year":"2022","unstructured":"Chowdary, P. et al. Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B. N. Engl. J. Med. 387, 237\u2013247 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4441_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","volume":"28","author":"TR Flotte","year":"2022","unstructured":"Flotte, T. R. et al. AAV gene therapy for Tay\u2013Sachs disease. Nat. Med. 28, 251\u2013259 (2022).","journal-title":"Nat. Med."},{"key":"4441_CR33","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","volume":"30","author":"J Sevigny","year":"2024","unstructured":"Sevigny, J. et al. Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results. Nat. Med. 30, 1406\u20131415 (2024).","journal-title":"Nat. Med."},{"key":"4441_CR34","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","volume":"177","author":"M Battaglia","year":"2006","unstructured":"Battaglia, M. et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177, 8338\u20138347 (2006).","journal-title":"J. Immunol."},{"key":"4441_CR35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1006\/cimm.1994.1193","volume":"156","author":"KM Aagaard-Tillery","year":"1994","unstructured":"Aagaard-Tillery, K. M. & Jelinek, D. F. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell. Immunol. 156, 493\u2013507 (1994).","journal-title":"Cell. Immunol."},{"key":"4441_CR36","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.111.078212","volume":"125","author":"S Sciarretta","year":"2012","unstructured":"Sciarretta, S. et al. Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation 125, 1134\u20131146 (2012).","journal-title":"Circulation"},{"key":"4441_CR37","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George, L. A. et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N. Engl. J. Med. 385, 1961\u20131973 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4441_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","volume":"199","author":"R Calcedo","year":"2009","unstructured":"Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. & Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381\u2013390 (2009).","journal-title":"J. Infect. Dis."},{"key":"4441_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/gt.2014.47","volume":"21","author":"Q Liu","year":"2014","unstructured":"Liu, Q. et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther. 21, 732\u2013738 (2014).","journal-title":"Gene Ther."},{"key":"4441_CR40","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/mt.2011.108","volume":"19","author":"V Monteilhet","year":"2011","unstructured":"Monteilhet, V. et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084\u20132091 (2011).","journal-title":"Mol. Ther."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04441-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04441-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:02:57Z","timestamp":1781791377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04441-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4441"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04441-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}